US Bancorp’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,814
| Closed | -$312K | – | 4307 |
|
|
2021
Q3 | $312K | Buy |
1,814
+87
| +5% | +$11.4K | ﹤0.01% | 1761 |
|
|
2021
Q2 | $216K | Sell |
1,727
-38
| -2% | -$4.79K | ﹤0.01% | 1943 |
|
|
2021
Q1 | $240K | Buy |
1,765
+58
| +3% | +$7.49K | ﹤0.01% | 1843 |
|
|
2020
Q4 | $218K | Buy |
1,707
+18
| +1% | +$2.11K | ﹤0.01% | 1839 |
|
|
2020
Q3 | $190K | Buy |
1,689
+802
| +90% | +$79.8K | ﹤0.01% | 1793 |
|
|
2020
Q2 | $85K | Buy |
+887
| New | +$85.5K | ﹤0.01% | 2191 |
|
|
2020
Q1 | – | Sell |
-19
| Closed | -$1K | – | 3869 |
|
|
2019
Q4 | $1K | Hold |
19
| – | – | ﹤0.01% | 3622 |
|
|
2019
Q3 | $1K | Buy |
+19
| New | +$824 | ﹤0.01% | 3542 |
|
|
2019
Q2 | – | Sell |
-72
| Closed | -$3K | – | 3715 |
|
|
2019
Q1 | $3K | Buy |
+72
| New | +$3.16K | ﹤0.01% | 3384 |
|
|
2018
Q3 | – | Sell |
-500
| Closed | -$24K | – | 3736 |
|
|
2018
Q2 | $24K | Hold |
500
| – | – | ﹤0.01% | 2880 |
|
|
2018
Q1 | $20K | Buy |
+500
| New | +$21.3K | ﹤0.01% | 2947 |
|
US Bancorp's XLRN Position: Q4 2021 in Review
US Bancorp sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 1,814 shares — an estimated $312K sold.
US Bancorp first reported a position in XLRN in Q1 2018 and held it in 11 quarters. The position peaked at $312K in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- US Bancorp reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- US Bancorp sold 1,814 Acceleron Pharma shares in Q4 2021, an estimated $312K.
- US Bancorp first reported a position in Acceleron Pharma in Q1 2018 and held it in 11 quarters.
- US Bancorp's Acceleron Pharma position peaked at $312K in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on US Bancorp's 13F filing for Q4 2021, filed 11 Feb 2022.